1
|
Richards SE, Bradshaw PR, Johnson CH, Stachulski AV, Athersuch TJ, Nicholson JK, Lindon JC, Wilson ID. Transacylation and hydrolysis of the acyl glucuronides of ibuprofen and its α-methyl-substituted analogues investigated by 1H NMR spectroscopy and computational chemistry: Implications for drug design. J Pharm Biomed Anal 2024; 246:116238. [PMID: 38805849 DOI: 10.1016/j.jpba.2024.116238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2024] [Revised: 05/15/2024] [Accepted: 05/17/2024] [Indexed: 05/30/2024]
Abstract
Drugs and drug metabolites containing a carboxylic-acid moiety can undergo in vivo conjugation to form 1-β-O-acyl-glucuronides (1-β-O-AGs). In addition to hydrolysis, these conjugates can undergo spontaneous acyl migration, and anomerisation reactions, resulting in a range of positional isomers. Facile transacylation has been suggested as a mechanism contributing to the toxicity of acyl glucuronides, with the kinetics of these processes thought to be a factor. Previous 1H NMR spectroscopic and HPLC-MS studies have been conducted to measure the degradation rates of the 1-β-O-AGs of three nonsteroidal anti-inflammatory drugs (ibufenac, R-ibuprofen, S-ibuprofen) and a dimethyl-analogue (termed here as "bibuprofen"). These studies have also determined the relative contributions of hydrolysis and acyl migration in both buffered aqueous solution, and human plasma. Here, a detailed kinetic analysis is reported, providing the individual rate constants for the acyl migration and hydrolysis reactions observed in buffer for each of the 4 AGs, together with the overall degradation rate constants of the parent 1-β-O-AGs. Computational modelling of the reactants and transition states of the transacylation reaction using density functional theory indicated differences in the activation energies that reflected the influence of both substitution and stereochemistry on the rate of transacylation/hydrolysis.
Collapse
Affiliation(s)
- Selena E Richards
- Department of Chemistry, Khalifa University, Abu Dhabi, United Arab Emirates
| | - Peter R Bradshaw
- Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Burlington Danes Building, London W12 0NN, UK
| | - Caroline H Johnson
- Department of Environmental Health Sciences, Yale School of Public Health, 60 College Street, New Haven, CT 06520-8034, USA
| | - Andrew V Stachulski
- Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, UK
| | - Toby J Athersuch
- Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Burlington Danes Building, London W12 0NN, UK
| | - Jeremy K Nicholson
- The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth WA6150, Australia; Institute of Global Health Innovation, Faculty of Medicine, Imperial College London, Level 1, Faculty Building, South Kensington Campus, London SW7 2NA, UK
| | - John C Lindon
- Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Burlington Danes Building, London W12 0NN, UK
| | - Ian D Wilson
- Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Burlington Danes Building, London W12 0NN, UK.
| |
Collapse
|
2
|
Lassfolk R, Leino R. Mechanism of Acyl Group Migration in Carbohydrates. Chemistry 2023; 29:e202301489. [PMID: 37265378 DOI: 10.1002/chem.202301489] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 05/30/2023] [Accepted: 06/02/2023] [Indexed: 06/03/2023]
Abstract
Acyl group migration has been the subject of several studies. Such migration processes may cause problems during synthesis, isolation, and purification of different acyl-bearing compounds, and have biological relevance, for example, in the metabolism of pharmaceuticals. Considering the recent evidence of acyl group migration being possible even over glycosidic bonds, it could be hypothesized to be involved also in the regulation of biological activity of natural polysaccharides in the host cells. Migrations are mostly observed in carbohydrates, typically having several hydroxyl groups near each other. Several studies have investigated the migration in a single or only a few different carbohydrate molecules, providing different suggestions for the mechanisms of migration, seldom supported by comprehensive computational investigations. In this concept article we discuss the recent progress on the mechanistic aspects of acyl group migration, with carbohydrates in particular focus.
Collapse
Affiliation(s)
- Robert Lassfolk
- Turku Centre for Chemical and Molecular Analytics, Åbo Akademi University, 20500, Turku, Finland
| | - Reko Leino
- Laboratory of Molecular Science and Engineering, Åbo Akademi University, 20500, Turku, Finland
| |
Collapse
|
3
|
Regueiro-Ren A, Sit SY, Chen Y, Chen J, Swidorski JJ, Liu Z, Venables BL, Sin N, Hartz RA, Protack T, Lin Z, Zhang S, Li Z, Wu DR, Li P, Kempson J, Hou X, Gupta A, Rampulla R, Mathur A, Park H, Sarjeant A, Benitex Y, Rahematpura S, Parker D, Phillips T, Haskell R, Jenkins S, Santone KS, Cockett M, Hanumegowda U, Dicker I, Meanwell NA, Krystal M. The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation. J Med Chem 2022; 65:11927-11948. [PMID: 36044257 DOI: 10.1021/acs.jmedchem.2c00879] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
GSK3640254 is an HIV-1 maturation inhibitor (MI) that exhibits significantly improved antiviral activity toward a range of clinically relevant polymorphic variants with reduced sensitivity toward the second-generation MI GSK3532795 (BMS-955176). The key structural difference between GSK3640254 and its predecessor is the replacement of the para-substituted benzoic acid moiety attached at the C-3 position of the triterpenoid core with a cyclohex-3-ene-1-carboxylic acid substituted with a CH2F moiety at the carbon atom α- to the pharmacophoric carboxylic acid. This structural element provided a new vector with which to explore structure-activity relationships (SARs) and led to compounds with improved polymorphic coverage while preserving pharmacokinetic (PK) properties. The approach to the design of GSK3640254, the development of a synthetic route and its preclinical profile are discussed. GSK3640254 is currently in phase IIb clinical trials after demonstrating a dose-related reduction in HIV-1 viral load over 7-10 days of dosing to HIV-1-infected subjects.
Collapse
Affiliation(s)
- Alicia Regueiro-Ren
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, Princeton, New Jersey08543, United States
| | - Sing-Yuen Sit
- Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Yan Chen
- Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Jie Chen
- Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Jacob J Swidorski
- Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Zheng Liu
- Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Brian L Venables
- Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Ny Sin
- Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Richard A Hartz
- Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Tricia Protack
- Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Zeyu Lin
- Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Sharon Zhang
- Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Zhufang Li
- Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Dauh-Rurng Wu
- Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States
| | - Peng Li
- Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States
| | - James Kempson
- Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States
| | - Xiaoping Hou
- Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States
| | - Anuradha Gupta
- Department of Discovery Synthesis; Bristol Myers Squibb Research and Early Development, Bangalore 560099, India
| | - Richard Rampulla
- Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States
| | - Arvind Mathur
- Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States
| | - Hyunsoo Park
- Bristol Myers Squibb Chemical and Synthetic Development, New Brunswick, New Jersey08901, United States
| | - Amy Sarjeant
- Bristol Myers Squibb Chemical and Synthetic Development, New Brunswick, New Jersey08901, United States
| | - Yulia Benitex
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Sandhya Rahematpura
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Dawn Parker
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Thomas Phillips
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Roy Haskell
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Susan Jenkins
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Kenneth S Santone
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Mark Cockett
- Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Umesh Hanumegowda
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Ira Dicker
- Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| | - Nicholas A Meanwell
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, Princeton, New Jersey08543, United States
| | - Mark Krystal
- Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States
| |
Collapse
|
4
|
Lassfolk R, Pedrón M, Tejero T, Merino P, Wärnå J, Leino R. Acyl Group Migration in Pyranosides as Studied by Experimental and Computational Methods. Chemistry 2022; 28:e202200499. [PMID: 35302249 PMCID: PMC9322027 DOI: 10.1002/chem.202200499] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Indexed: 12/14/2022]
Abstract
Acyl group migration affects the synthesis, isolation, manipulation and purification of all acylated organic compounds containing free hydroxyl groups, in particular carbohydrates. While several isolated studies on the migration phenomenon in different buffers have been reported, comprehensive insights into the overall migration process in different monosaccharides under similar conditions have been lacking. Here, we have studied the acyl migration in different monosaccharides using five different acyl groups by a combination of experimental, kinetic and theoretical tools. The results show that the anomeric configuration in the monosaccharide has a major influence on the migration rate, together with the relative configurations of the other hydroxyl groups and the nature of the migrating acyl group. Full mechanistic model, based on computations, demonstrates that the acyl migration proceeds through an anionic stepwise mechanism with linear dependence on the [OH−] and the pKa of the hydroxyl group toward which the acyl group is migrating.
Collapse
Affiliation(s)
- Robert Lassfolk
- Laboratory of Molecular Science and Engineering, Åbo Akademi University, 20500, Turku, Finland
| | - Manuel Pedrón
- Institute of Biocomputation & Physics of Complex Systems (BIFI), University of Zaragoza, 50009, Zaragoza, Spain
| | - Tomás Tejero
- Institute of Chemical Synthesis & Homogeneous Catalysis (ISQCH), University of Zaragoza, 50009, Zaragoza, Spain
| | - Pedro Merino
- Institute of Biocomputation & Physics of Complex Systems (BIFI), University of Zaragoza, 50009, Zaragoza, Spain
| | - Johan Wärnå
- Laboratory of Industrial Chemistry and Reaction Engineering, Åbo Akademi University, 20500, Turku, Finland
| | - Reko Leino
- Laboratory of Molecular Science and Engineering, Åbo Akademi University, 20500, Turku, Finland
| |
Collapse
|
5
|
Shimada H, Ikuta H, Kumazawa K, Nomi M, Shiojiri M, Kawase A, Iwaki M. Relationship between the risk of idiosyncratic drug toxicity and formation and degradation profiles of acyl-glucuronide metabolites of nonsteroidal anti-inflammatory drugs in rat liver microsomes. Eur J Pharm Sci 2022; 174:106193. [PMID: 35447304 DOI: 10.1016/j.ejps.2022.106193] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 03/15/2022] [Accepted: 04/15/2022] [Indexed: 01/17/2023]
Abstract
Acyl glucuronides (AGs) are considered to cause idiosyncratic drug toxicity (IDT), and evaluating the chemical instability of AGs may be useful for predicting the IDT risk of novel drug candidates. However, AGs show variations in their chemical instability, degree of formation, and enzymatic hydrolysis. Therefore, we evaluated the degree of AG formation, enzymatic hydrolysis, and chemical instability in liver microsomes and their relationship with IDT risk. Nonsteroidal anti-inflammatory drugs (NSAIDs) were classified into three categories in terms of their IDT risk as parent drugs: safe (SA), warning (WA), and withdrawn (WDN). To evaluate the enzymatic and non-enzymatic degradation of AG, the parent drugs were incubated with rat liver microsomes in the absence or presence of AG hydrolase inhibitors. The degree of AG formation and disappearance was considered as the rate constant. For all NSAIDs investigated, the number of AGs formed notably increased following addition of AG hydrolase inhibitors. Particularly, AG was produced by WDN drugs at a lower level than that produced by WA and SA drugs in the absence of AG hydrolase inhibitors but was significantly increased after adding AG hydrolase inhibitors. The rate constants of AG formation and non-enzymatic AG disappearance did not significantly differ among the WDN, WA, and SA drugs, whereas the rate constant of enzymatic AG disappearance of WDN drugs tended to be higher than those of WA and SA drugs. In conclusion, we evaluated the enzymatic degradation and chemical instability of AG by simultaneously producing it in liver microsomes. This method enables evaluation of AG degradation without preparing AG. Moreover, we determined the relationship between enzymatic AG degradation in rat liver microsomes and IDT risk.
Collapse
Affiliation(s)
- Hiroaki Shimada
- Faculty of Pharmacy, Kindai University, Osaka 577-8502, Japan
| | - Hiroyuki Ikuta
- Faculty of Pharmacy, Kindai University, Osaka 577-8502, Japan
| | | | - Manato Nomi
- Faculty of Pharmacy, Kindai University, Osaka 577-8502, Japan
| | - Mayumi Shiojiri
- Faculty of Pharmacy, Kindai University, Osaka 577-8502, Japan
| | - Atsushi Kawase
- Faculty of Pharmacy, Kindai University, Osaka 577-8502, Japan
| | - Masahiro Iwaki
- Faculty of Pharmacy, Kindai University, Osaka 577-8502, Japan; Pharmaceutical Research and Technology Institute, Kindai University, Osaka 577-8502, Japan; Antiaging Center, Kindai University, Osaka 577-8502, Japan.
| |
Collapse
|
6
|
Lassfolk R, Bertuzzi S, Ardá A, Wärnå J, Jiménez‐Barbero J, Leino R. Kinetic Studies of Acetyl Group Migration between the Saccharide Units in an Oligomannoside Trisaccharide Model Compound and a Native Galactoglucomannan Polysaccharide. Chembiochem 2021; 22:2986-2995. [PMID: 34405515 PMCID: PMC8597014 DOI: 10.1002/cbic.202100374] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Indexed: 01/11/2023]
Abstract
Acyl group migration is a fundamental phenomenon in carbohydrate chemistry, recently shown to take place also between two non-adjacent hydroxyl groups, across the glycosidic bond, in a β-(1→4)-linked mannan trisaccharide model compound. With the central mannoside unit containing acetyl groups at the O2 and O3 positions, the O2-acetyl was in the earlier study shown to migrate to O6 of the reducing end. Potential implications of the general acyl migration process on cell signaling events and plant growth in nature are intriguing open questions. In the present work, migration kinetics in this original trisaccharide model system were studied in more detail together with potential interactions of the model compound and the migration products with DC-SIGN lectin. Furthermore, we demonstrate here for the first time that similar migration may also take place in native polysaccharides, here represented by galactoglucomannan from Norway spruce.
Collapse
Affiliation(s)
- Robert Lassfolk
- Laboratory of Molecular Science and EngineeringÅbo Akademi University20500TurkuFinland
| | - Sara Bertuzzi
- Chemical Glycobiology LaboratoryCIC bioGUNEBizkaia Technology Park, Building 80048160DerioSpain
| | - Ana Ardá
- Chemical Glycobiology LaboratoryCIC bioGUNEBizkaia Technology Park, Building 80048160DerioSpain
- Ikerbasque, Basque Foundation for SciencePlaza Euskadi 548009BilbaoSpain
| | - Johan Wärnå
- Laboratory of Industrial Chemistry and Reaction EngineeringÅbo Akademi University20500TurkuFinland
| | - Jesús Jiménez‐Barbero
- Chemical Glycobiology LaboratoryCIC bioGUNEBizkaia Technology Park, Building 80048160DerioSpain
- Ikerbasque, Basque Foundation for SciencePlaza Euskadi 548009BilbaoSpain
- Department of Organic & Inorganic ChemistryUniversity of the Basque Country, UPV/EHU48940LeioaBizkaiaSpain
| | - Reko Leino
- Laboratory of Molecular Science and EngineeringÅbo Akademi University20500TurkuFinland
| |
Collapse
|
7
|
Rennie GR, Barden TC, Bernier SG, Carvalho A, Deming R, Germano P, Hudson C, Im GYJ, Iyengar RR, Jia L, Jung J, Kim E, Lee TWH, Mermerian A, Moore J, Nakai T, Perl NR, Tobin J, Zimmer DP, Renhowe PA. Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator. Bioorg Med Chem Lett 2021; 40:127886. [PMID: 33662540 DOI: 10.1016/j.bmcl.2021.127886] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 02/09/2021] [Accepted: 02/10/2021] [Indexed: 10/22/2022]
Abstract
Soluble guanylate cyclase (sGC) is a clinically validated therapeutic target in the treatment of pulmonary hypertension. Modulators of sGC have the potential to treat diseases that are affected by dysregulation of the NO-sGC-cGMP signal transduction pathway. This letter describes the SAR efforts that led to the discovery of CYR715, a novel carboxylic acid-containing sGC stimulator, with an improved metabolic profile relative to our previously described stimulator, IWP-051. CYR715 addressed potential idiosyncratic drug toxicity (IDT) liabilities associated with the formation of reactive, migrating acyl glucuronides (AG) found in related carboxylic acid-containing analogs and demonstrated high oral bioavailability in rat and dose-dependent hemodynamic pharmacology in normotensive Sprague-Dawley rats.
Collapse
Affiliation(s)
- Glen R Rennie
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Timothy C Barden
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Sylvie G Bernier
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Andrew Carvalho
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Renee Deming
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Peter Germano
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Colleen Hudson
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - G-Yoon J Im
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Rajesh R Iyengar
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Lei Jia
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Joon Jung
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Elise Kim
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Thomas W-H Lee
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Ara Mermerian
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Joel Moore
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Takashi Nakai
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Nicholas R Perl
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Jenny Tobin
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Daniel P Zimmer
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States
| | - Paul A Renhowe
- Cyclerion Therapeutics, Inc., 301 Binney Street Cambridge, MA 02142, United States.
| |
Collapse
|
8
|
Acyl glucuronide reactivity in perspective. Drug Discov Today 2020; 25:1639-1650. [PMID: 32681884 DOI: 10.1016/j.drudis.2020.07.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 06/22/2020] [Accepted: 07/08/2020] [Indexed: 12/12/2022]
Abstract
Acyl glucuronidation is a common metabolic fate for acidic drugs and their metabolites and, because these metabolites are reactive, they have been linked to adverse drug reactions (ADRs) and drug withdrawals. However, alternative routes of metabolism leading to reactive metabolites (e.g., oxidations and acyl-CoA thioesters) mean that unambiguous proof that acyl glucuronides are toxic is lacking. Here, we review the synthesis and reactivity of these metabolites, and describe the use of molecular modelling and in vitro and in vivo reactivity assessment of acyl glucuronide reactivity. Based on the emerging structure-dependent differences in reactivity and protein adduction methods for risk assessment for acyl glucuronide-forming acid drugs or drug candidates in drug discovery/development are suggested.
Collapse
|
9
|
Walles M, Brown AP, Zimmerlin A, End P. New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl Glucuronides. Chem Res Toxicol 2020; 33:1551-1560. [PMID: 32525307 DOI: 10.1021/acs.chemrestox.0c00131] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Drug-induced liver injury (DILI) remains one of the key challenges in drug development due to the mechanisms of action being multifactorial in nature. This is particularly the case for idiosyncratic DILI which occurs in a very low frequency in humans (e.g., 1:10,000). Despite perceptions that acyl glucuronide metabolites are defacto risks for DILI, scientific evidence suggests that acyl glucuronide formation alone does not pose an increased risk compared to other drug metabolites. This applies in particular to those acyl glucuronides which are not reactive and do not form covalent adducts with proteins. The goal of this paper is to provide guidance on preclinical and clinical strategies to evaluate the potential for acyl glucuronide formation to contribute to DILI. A key element of our proposed safety assessment is to investigate whether a particular acyl glucuronide is reactive or not and whether systemic exposure in humans can be demonstrated in animal toxicology studies following administration of the parent drug. While standard animal toxicology studies can identify overtly hepatotoxic compounds, these studies are not predictive for drugs that produce idiosyncratic forms of DILI. In addition, we do not recommend conducting toxicology studies of administered individual acyl glucuronides due to differences in pharmacokinetic and dispositional properties from the endogenously produced metabolites. Once a drug candidate has entered clinical trials, the focus should be on clinical safety data and emerging risk-benefit analysis.
Collapse
Affiliation(s)
- Markus Walles
- PK Sciences, Novartis Institutes for Biomedical Research, Novartis Campus, 4052 Basel, Switzerland
| | - Alan P Brown
- Preclinical Safety, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Alfred Zimmerlin
- PK Sciences, Novartis Institutes for Biomedical Research, Novartis Campus, 4052 Basel, Switzerland
| | - Peter End
- PK Sciences, Novartis Institutes for Biomedical Research, Novartis Campus, 4052 Basel, Switzerland
| |
Collapse
|
10
|
Bradshaw PR, Richards SE, Wilson ID, Stachulski AV, Lindon JC, Athersuch TJ. Kinetic modelling of acyl glucuronide and glucoside reactivity and development of structure–property relationships. Org Biomol Chem 2020; 18:1389-1401. [DOI: 10.1039/c9ob02008j] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Detailed kinetic and transition structure modelling to rationalise the differences in reactivity observed between the acyl glucuronide and glucoside metabolites of a series of phenylacetic acid analogues.
Collapse
Affiliation(s)
- Peter R. Bradshaw
- Department of Metabolism
- Digestion and Reproduction
- Faculty of Medicine
- Imperial College London
- London
| | - Selena E. Richards
- Department of Chemistry
- Khalifa University of Science and Technology
- Abu Dhabi
- United Arab Emirates
| | - Ian D. Wilson
- Department of Metabolism
- Digestion and Reproduction
- Faculty of Medicine
- Imperial College London
- London
| | - Andrew V. Stachulski
- Department of Chemistry
- The Robert Robinson Laboratories
- University of Liverpool
- Liverpool L69 7ZD
- UK
| | - John C. Lindon
- Department of Metabolism
- Digestion and Reproduction
- Faculty of Medicine
- Imperial College London
- London
| | - Toby J. Athersuch
- Department of Metabolism
- Digestion and Reproduction
- Faculty of Medicine
- Imperial College London
- London
| |
Collapse
|
11
|
Baba A, Yamada K, Satoh T, Watanabe K, Yoshioka T. Chemo-Enzymatic Synthesis, Structural and Stereochemical Characterization, and Intrinsic Degradation Kinetics of Diastereomers of 1-β- O-Acyl Glucuronides Derived from Racemic 2-{4-[(2-Methylprop-2-en-1-yl)amino]phenyl}propanoic Acid. ACS OMEGA 2018; 3:4932-4940. [PMID: 31458709 PMCID: PMC6641924 DOI: 10.1021/acsomega.8b00443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 04/24/2018] [Indexed: 06/10/2023]
Abstract
Alminoprofen, (RS)-2-{4-[(2-methylprop-2-en-1-yl)amino]phenyl}propanoic acid (ALP) 1, is a racemic drug categorized as a 2-arylpropanoic acid-class nonsteroidal anti-inflammatory drug. Pharmacokinetic studies of 1 in patients have revealed that the corresponding acyl glucuronide 5 is a major urinary metabolite, but little is known about the structure and stereochemistry of 5. The present work describes the synthesis of a diastereomeric mixture of 1-β-O-acyl glucuronides (2RS)-5 from 1 and methyl 2,3,4-tri-O-acetyl-1-bromo-1-deoxy-α-d-glucopyranuronate 2 using our chemo-enzymatic method that has complete specificity for the β-configuration. The structure of (2RS)-5 was characterized by 1H and 13C NMR spectroscopy and high-resolution mass spectrometry as well as by complete hydrolysis by β-glucuronidase. The absolute stereochemistry of (2RS)-5 was determined by comparison with (2R)-5 synthesized alternatively from (2R)-1 and 2. Compound (2R)-1 was prepared in two steps starting from chiral (R)-2-(4-nitrophenyl)propanoic acid (2R)-6. Chiral resolution of (2RS)-1 was achieved using a chiral high-performance liquid chromatography column, and its stereochemistry was determined by comparison with (2R)-1. The intrinsic degradation rate constant of (2R)-5 was 0.405 ± 0.002 h-1, which is approximately twice that of (2S)-5 (the k value was 0.226 ± 0.002 h-1) under physiological conditions (pH 7.40, 37 °C).
Collapse
Affiliation(s)
- Akiko Baba
- Department
of Medicinal Chemistry and Department of Pharmaceutics, Faculty
of Pharmaceutical Sciences, Hokkaido University
of Science, 7-15-4-1
Maeda, Teine, Sapporo, Hokkaido 006-8585, Japan
| | - Koki Yamada
- Department
of Medicinal Chemistry and Department of Pharmaceutics, Faculty
of Pharmaceutical Sciences, Hokkaido University
of Science, 7-15-4-1
Maeda, Teine, Sapporo, Hokkaido 006-8585, Japan
| | - Takashi Satoh
- Department
of Medicinal Chemistry and Department of Pharmaceutics, Faculty
of Pharmaceutical Sciences, Hokkaido University
of Science, 7-15-4-1
Maeda, Teine, Sapporo, Hokkaido 006-8585, Japan
| | - Kazuhiro Watanabe
- Department
of Medicinal Chemistry and Department of Pharmaceutics, Faculty
of Pharmaceutical Sciences, Hokkaido University
of Science, 7-15-4-1
Maeda, Teine, Sapporo, Hokkaido 006-8585, Japan
| | - Tadao Yoshioka
- Department
of Medicinal Chemistry and Department of Pharmaceutics, Faculty
of Pharmaceutical Sciences, Hokkaido University
of Science, 7-15-4-1
Maeda, Teine, Sapporo, Hokkaido 006-8585, Japan
| |
Collapse
|
12
|
Camilleri P, Buch A, Soldo B, Hutt AJ. The influence of physicochemical properties on the reactivity and stability of acyl glucuronides. Xenobiotica 2017; 48:958-972. [DOI: 10.1080/00498254.2017.1384967] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
| | - Akshay Buch
- Aerpio Therapeutics, Inc., Cincinnati, OH, USA, and
| | - Brandi Soldo
- Aerpio Therapeutics, Inc., Cincinnati, OH, USA, and
| | - Andrew J. Hutt
- Department of Pharmacy, Pharmacology and Postgraduate Medicine, University of Hertfordshire, College Lane, Hatfield, UK
| |
Collapse
|
13
|
Meanwell NA. The Influence of Bioisosteres in Drug Design: Tactical Applications to Address Developability Problems. TACTICS IN CONTEMPORARY DRUG DESIGN 2014; 9. [PMCID: PMC7416817 DOI: 10.1007/7355_2013_29] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The application of bioisosteres in drug discovery is a well-established design concept that has demonstrated utility as an approach to solving a range of problems that affect candidate optimization, progression, and durability. In this chapter, the application of isosteric substitution is explored in a fashion that focuses on the development of practical solutions to problems that are encountered in typical optimization campaigns. The role of bioisosteres to affect intrinsic potency and selectivity, influence conformation, solve problems associated with drug developability, including P-glycoprotein recognition, modulating basicity, solubility, and lipophilicity, and to address issues associated with metabolism and toxicity is used as the underlying theme to capture a spectrum of creative applications of structural emulation in the design of drug candidates.
Collapse
|
14
|
Monrad RN, Errey JC, Barry CS, Iqbal M, Meng X, Iddon L, Perrie JA, Harding JR, Wilson ID, Stachulski AV, Davis BG. Dissecting the reaction of Phase II metabolites of ibuprofen and other NSAIDS with human plasma protein. Chem Sci 2014. [DOI: 10.1039/c4sc01329h] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Blood-protein transacylation/glycosylation reactivity of glucuronides may distinguish beneficial (e.g., ibuprofen) and toxic (e.g., ibufenac) drugs.
Collapse
Affiliation(s)
- Rune Nygaard Monrad
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford, UK
| | - James C. Errey
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford, UK
| | - Conor S. Barry
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford, UK
| | - Mazhar Iqbal
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - Xiaoli Meng
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - Lisa Iddon
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - Jennifer A. Perrie
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - John R. Harding
- Drug Metabolism and Pharmacokinetics
- Astra Zeneca
- Cheshire SK10 4TG, UK
| | - Ian D. Wilson
- Drug Metabolism and Pharmacokinetics
- Astra Zeneca
- Cheshire SK10 4TG, UK
| | - Andrew V. Stachulski
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - Benjamin G. Davis
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford, UK
| |
Collapse
|
15
|
Stachulski AV, Baillie TA, Kevin Park B, Scott Obach R, Dalvie DK, Williams DP, Srivastava A, Regan SL, Antoine DJ, Goldring CEP, Chia AJL, Kitteringham NR, Randle LE, Callan H, Castrejon JL, Farrell J, Naisbitt DJ, Lennard MS. The Generation, Detection, and Effects of Reactive Drug Metabolites. Med Res Rev 2012; 33:985-1080. [DOI: 10.1002/med.21273] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Andrew V. Stachulski
- Department of Chemistry, Robert Robinson Laboratories; University of Liverpool; Liverpool; L69 7ZD; UK
| | - Thomas A. Baillie
- School of Pharmacy; University of Washington; Box 357631; Seattle; Washington; 98195-7631
| | - B. Kevin Park
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - R. Scott Obach
- Pharmacokinetics, Dynamics and Metabolism; Pfizer Worldwide Research & Development; Groton; Connecticut 06340
| | - Deepak K. Dalvie
- Pharmacokinetics, Dynamics and Metabolism; Pfizer Worldwide Research & Development; La Jolla; California 94121
| | - Dominic P. Williams
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Abhishek Srivastava
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Sophie L. Regan
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Daniel J. Antoine
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Christopher E. P. Goldring
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Alvin J. L. Chia
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Neil R. Kitteringham
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Laura E. Randle
- School of Pharmacy and Biomolecular Sciences, Faculty of Science; Liverpool John Moores University; James Parsons Building, Byrom Street; Liverpool L3 3AF; UK
| | - Hayley Callan
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - J. Luis Castrejon
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - John Farrell
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Dean J. Naisbitt
- Department of Molecular and Clinical Pharmacology; MRC Centre for Drug Safety Science; Institute of Translational Medicine; University of Liverpool; Sherrington Buildings, Ashton Street; Liverpool L69 3GE; UK
| | - Martin S. Lennard
- Academic Unit of Medical Education; University of Sheffield; 85 Wilkinson Street; Sheffield S10 2GJ; UK
| |
Collapse
|
16
|
Baba A, Yoshioka T. Complementary and Synergistic Roles in Enzyme-Catalyzed Regioselective and Complete Hydrolytic Deprotection of O-Acetylated β-d-Glucopyranosides of N-Arylacetohydroxamic Acids. J Org Chem 2012; 77:1675-84. [DOI: 10.1021/jo202123s] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Akiko Baba
- Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka-cho, Otaru, Hokkaido 047-0264,
Japan
| | - Tadao Yoshioka
- Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka-cho, Otaru, Hokkaido 047-0264,
Japan
| |
Collapse
|
17
|
In silico prediction of acyl glucuronide reactivity. J Comput Aided Mol Des 2011; 25:997-1005. [DOI: 10.1007/s10822-011-9479-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2011] [Accepted: 10/12/2011] [Indexed: 11/26/2022]
|
18
|
Baba A, Yoshioka T. Characterization of chemo- and regioselectivity in enzyme-catalyzed consecutive hydrolytic deprotection of methyl acetyl derivatives of 1-β-O-acyl glucuronides. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/j.molcatb.2010.12.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
19
|
Affiliation(s)
- Rajeshwar P Verma
- Department of Chemistry, Pomona College, 645 North College Avenue, Claremont, California 91711, USA.
| | | |
Collapse
|
20
|
Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park BK. Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 2011; 31:367-95. [PMID: 20830700 DOI: 10.1002/bdd.720] [Citation(s) in RCA: 135] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Acyl glucuronidation is the major metabolic conjugation reaction of most carboxylic acid drugs in mammals. The physiological consequences of this biotransformation have been investigated incompletely but include effects on drug metabolism, protein binding, distribution and clearance that impact upon pharmacological and toxicological outcomes. In marked contrast, the exceptional but widely disparate chemical reactivity of acyl glucuronides has attracted far greater attention. Specifically, the complex transacylation and glycation reactions with proteins have provoked much inconclusive debate over the safety of drugs metabolised to acyl glucuronides. It has been hypothesised that these covalent modifications could initiate idiosyncratic adverse drug reactions. However, despite a large body of in vitro data on the reactions of acyl glucuronides with protein, evidence for adduct formation from acyl glucuronides in vivo is limited and potentially ambiguous. The causal connection of protein adduction to adverse drug reactions remains uncertain. This review has assessed the intrinsic reactivity, metabolic stability and pharmacokinetic properties of acyl glucuronides in the context of physiological, pharmacological and toxicological perspectives. Although numerous experiments have characterised the reactions of acyl glucuronides with proteins, these might be attenuated substantially in vivo by rapid clearance of the conjugates. Consequently, to delineate a relationship between acyl glucuronide formation and toxicological phenomena, detailed pharmacokinetic analysis of systemic exposure to the acyl glucuronide should be undertaken adjacent to determining protein adduct concentrations in vivo. Further investigation is required to ascertain whether acyl glucuronide clearance is sufficient to prevent covalent modification of endogenous proteins and consequentially a potential immunological response.
Collapse
Affiliation(s)
- Sophie L Regan
- MRC Centre for Drug Safety Science, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3GE, UK.
| | | | | | | | | | | |
Collapse
|
21
|
Karlsson ES, Johnson CH, Sarda S, Iddon L, Iqbal M, Meng X, Harding JR, Stachulski AV, Nicholson JK, Wilson ID, Lindon JC. High-performance liquid chromatography/mass spectrometric and proton nuclear magnetic resonance spectroscopic studies of the transacylation and hydrolysis of the acyl glucuronides of a series of phenylacetic acids in buffer and human plasma. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2010; 24:3043-3051. [PMID: 20872637 DOI: 10.1002/rcm.4740] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The use of high-performance liquid chromatography/mass spectrometry (HPLC/MS) and proton nuclear magnetic resonance ((1)H NMR) spectroscopy for the kinetic analysis of acyl glucuronide (AG) isomerisation and hydrolysis of the 1-β-O-acyl glucuronides (1-β-O-AG) of phenylacetic acid, (R)- and (S)-α-methylphenylacetic acid and α,α-dimethylphenylacetic acid is described and compared. Each AG was incubated in both aqueous buffer, at pH 7.4, and control human plasma at 37°C. Aliquots of these incubations, taken throughout the reaction time-course, were analysed by HPLC/MS and (1)H NMR spectroscopy. In buffer, transacylation reactions predominated, with relatively little hydrolysis to the free aglycone observed. In human plasma incubations the calculated rates of reaction were much faster than for buffer and, in contrast to the observations in buffer, hydrolysis to the free aglycone was a significant contributor to the overall reaction.A diagnostic analytical methodology based on differential mass spectrometric fragmentation of 1-β-O-AGs compared to the 2-, 3- and 4-positional isomers, which enables selective determination of the former, was confirmed and applied. These findings show that HPLC/MS offers a viable alternative to the more commonly used NMR spectroscopic approach for the determination of the transacylation and hydrolysis reactions of these AGs, with the major advantage of having the capability to do so in a complex biological matrix such as plasma.
Collapse
Affiliation(s)
- Elin S Karlsson
- Department of Clinical Pharmacology, Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, Macclesfield, Cheshire SK10 4TG, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Vaz ADN, Wang WW, Bessire AJ, Sharma R, Hagen AE. A rapid and specific derivatization procedure to identify acyl-glucuronides by mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2010; 24:2109-2121. [PMID: 20552710 DOI: 10.1002/rcm.4621] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
A simple procedure is described to identify acyl-glucuronides by coupled liquid chromatography/mass spectrometry after derivatization to a hydroxamic acid with hydroxylamine. The reaction specificity obviates the need for isolation of the acyl-glucuronide from an extract. Glucuronides derived from carbamic acids, and alkyl- and aromatic amines, are inert to the derivatization reaction conditions, making the hydroxamic acid derivative a fingerprint for acyl-glucuronides.
Collapse
Affiliation(s)
- Alfin D N Vaz
- Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA.
| | | | | | | | | |
Collapse
|
23
|
Baba A, Yoshioka T. Structure−Activity Relationships for the Degradation Reaction of 1-β-O-Acyl Glucuronides. Part 3: Electronic and Steric Descriptors Predicting the Reactivity of Aralkyl Carboxylic Acid 1-β-O-Acyl Glucuronides. Chem Res Toxicol 2009; 22:1998-2008. [DOI: 10.1021/tx9002963] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Akiko Baba
- Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka-cho, Otaru, Hokkaido 047-0264, Japan
| | - Tadao Yoshioka
- Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka-cho, Otaru, Hokkaido 047-0264, Japan
| |
Collapse
|